The purpose of this study is to compare the efficacy and toxicity of early stage endometrial cancer based on molecular classification and conventional risk stratification adjuvant therapy decision-making, and to provide high-quality evidence-based medical evidence for individualized adjuvant therapy selection under the guidance of fine stratification system of endometrial cancer.
Women aged 18-75.
Patients with newly histologically confirmed Endometrioid adenocarcinoma.
ECOG score 0-2
Surgery consisting of a total hysterectomy and bilateral salpingo-oophorectomy, pelvic lymphadenectomy or sentinel lymph node biopsy, with or without para-aortic lymphadenectomy, oophorectomy
Not FIGO stage I-II.
Residual tumor or positive margin.
Mixed carcinoma, sarcoma or carcinosarcoma
Previous history of malignant tumor
Peking Union Medical College Hospital
Lead sponsor
The First Affiliated Hospital of Air Force Medicial University
Collaborator
The Second Affiliated Hospital of Dalian Medical University
Collaborator
Second Hospital of Jilin University
Collaborator
First Affiliated Hospital Xi'an Jiaotong University
Collaborator
The Affiliated Hospital of Inner Mongolia Medical University
Collaborator
Third Affiliated Hospital of Xinjiang Medical University
Collaborator
Peking University First Hospital
Collaborator
940 Hospital of the People's Liberation Army Joint Logistic Support Force
Collaborator
Xiangya Hospital of Central South University
Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborator